Fig. 7. JQ1 represses the enhancer-promoter interaction of BRCA1.

Slides:

Advertisements

Similar presentations

Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Advertisements

Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.

BET inhibition and depletion repress the expression of BRCA1 and RAD51

Volume 44, Issue 3, Pages (November 2011)

JQ1 directly represses the promoter activities of BRCA1 and RAD51

Fig. 3. BET inhibition reduces homologous recombination.

3D Chromosome Regulatory Landscape of Human Pluripotent Cells

Lucas J.T. Kaaij, Robin H. van der Weide, René F. Ketting, Elzo de Wit

Formation of Chromosomal Domains by Loop Extrusion

Cytotoxicity of MSP samples to normal and cancer cell lines.

Chromatin regulation upon recruitment of HOTAIR

Nuclear calcium signaling drives nuclear actin polymerization in T cells. Nuclear calcium signaling drives nuclear actin polymerization in T cells. (A)

Comparing previous simulation work with current study.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Tfr cells’ transcriptomic profile distinguishes them from Treg and Tfh cells. Tfr cells’ transcriptomic profile distinguishes them from Treg and Tfh cells.

Fig. 1. Drug combination screen identifies BETi as acting synergistically with PARPi. Drug combination screen identifies BETi as acting synergistically.

Volume 67, Issue 6, Pages e6 (September 2017)

Volume 44, Issue 3, Pages (November 2011)

Fig. 2. BET inhibition enhances PARPi-induced DNA damage.

Tukey boxplots overlaid on data points from objective and subjective measures, displaying results from study 1. Tukey boxplots overlaid on data points.

Differential expression of TRM markers by donor- and recipient-derived T cells with time. Differential expression of TRM markers by donor- and recipient-derived.

Fig. 7 Correlation of NHP and human ISGs.

STAT4 facilitates a permissive epigenetic landscape (H3K4me3) in activated NK cells. STAT4 facilitates a permissive epigenetic landscape (H3K4me3) in activated.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Fig. 1 Movement percepts for all participants.

Genetic mapping and epigenetic landscape of RUNX3 locus overlapping rs

Fig. 4. Peanut-specific TH2A cells are specifically targeted during immunotherapy. Peanut-specific TH2A cells are specifically targeted during immunotherapy.

Fig. 2 Ro60 commensal bacteria are common among lupus and healthy subjects without overt dysbiosis of the fecal, oral, or skin microbiome. Ro60 commensal.

Fig. 1 ZIKV RNA in blood and tissues.

Fig. 7 Bacterial dependency networks in IgA deficiency and HDs.

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Fig. 4 p100/TSN enables E2F1 to interact with alternatively spliced transcripts. p100/TSN enables E2F1 to interact with alternatively spliced transcripts.

Fig. 4 Deorphanization of quinine and mefloquine protein targets.

Fig. 3. BET inhibition reduces homologous recombination.

Fig. 5 E2F1 also interacts with alternatively spliced transcripts from the MECOM gene. E2F1 also interacts with alternatively spliced transcripts from.

Single-base validation using ligation-amplification method and qPCR

Distinct enhancer binding of CEBPA in WT GMPs versus p30 L-GMPs

Fig. 4 CEBPA-p30 mediated activation of Nt5e expression.

MYC degradation screen identifies a compound that stabilizes MYC protein. MYC degradation screen identifies a compound that stabilizes MYC protein. (A)

Fig. 6 Metarrestin treatment reduces pre-RNA synthesis and Pol I occupancy at rDNA without changing rDNA chromatin states. Metarrestin treatment reduces.

Fig. 1 Cryo-EM structure of yeast Elp123 showing its active site.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

The prostate cancer risk variant rs regulates multiple gene expression through extreme long-range chromatin interaction to control tumor progression.

Fig. 3 The rs risk enhancer is a hub for intrachromosomal and interchromosomal interactions. The rs risk enhancer is a hub for intrachromosomal.

Fig. 6 RUNX/CBFB interaction inhibitor, Ro5-3335, significantly decreases mouse neurofibroma growth in vivo. RUNX/CBFB interaction inhibitor, Ro5-3335,

Fig. 2 Expressions of cll, abd-A, and Abd-B by qRT-PCR.

Volume 72, Issue 4, Pages e11 (November 2018)

Fig. 4. Paclitaxel promotes the expression of invasive isoforms of MENA in the primary breast cancer microenvironment. Paclitaxel promotes the expression.

Fig. 4 Interactions between intensity and polarization contrasts.

Fig. 4 Differential histone modifications at promoters in various brain cell populations. Differential histone modifications at promoters in various brain.

Fig. 2 Effect of CSF sTREM2– and CSF sTREM2–to–p-tau181 ratio on changes in cognition. Effect of CSF sTREM2– and CSF sTREM2–to–p-tau181 ratio on changes.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 4 ID1 is a direct CREB target.

Tregs preferentially regulate TH2 cytokines in skin.

Fig. 1 Topology of places and city block complexity.

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Multiplexed four- and eight-channel devices for rapid processing

Fig. 1. Construction of human liver seed grafts.

Fig. 2 BX795 is nontoxic to HCE cells at therapeutic concentration.

Fig. 2 Particles detected in snow samples collected at different locations from Europe to the Arctic. Particles detected in snow samples collected at different.

Fig. 1 RNA methyltransferase METTL14 and demethylase ALKBH5 promote growth and invasion of breast cancer cells. RNA methyltransferase METTL14 and demethylase.

Fig. 5 Foxp3 promotes functional recruitment of Bcl11b in Treg cells.

Fig. 2 Physical properties and measured responses of the sensors.

REV-ERBα deficiency alters the epigenetic landscape and differentially affects clock gene expression in ILC3 subsets. REV-ERBα deficiency alters the epigenetic.

Fig. 8 Immune correlates of protection.

Fig. 3 Gene expression analysis in 48-plex drug treatment experiments.

Fig. 2 Combined transcriptome profiling, ChIP-seq, and ATAC-seq analysis identifies 14 highly plausible direct targets of Runx. Combined transcriptome.

Fig. 5 Schematics illustrating enhancement in April tornado activity due to SST. Schematics illustrating enhancement in April tornado activity due to SST.

Fig. 5 Enhancers and super-enhancers identified in various brain cell populations. Enhancers and super-enhancers identified in various brain cell populations.

Cxxc1-deficient TH17 cells exhibit a Treg cell–like expression profile

Presentation transcript:

Fig. 7. JQ1 represses the enhancer-promoter interaction of BRCA1. JQ1 represses the enhancer-promoter interaction of BRCA1. (A) H3K27Ac, H3K4me1, H3K4me3 profiles in MDA-MB-231. Right and left rectangle frame areas indicate the BRCA1 promoter and enhancer locus 2, respectively, which were used for the BRCA1 promoter-enhancer reporter construct. Upper schematic illustration indicates the construction of the BRCA1 promoter-enhancer reporter. Lower schematic illustrates the Xba I restriction sites in BRCA1 promoter and enhancer loci. P in red indicates promoter, and E in black indicates enhancer. Numbers 1 to 7 indicate seven Xba I restriction sites in the enhancer locus. The position of the BRCA1 gene is indicated below. (B) H3K27Ac in VCaP cells (top) and BRD2/3/4 profiles in VCaP treated with DMSO or JQ1 (bottom). (C) H3K27Ac, H3K4me1, H3K4me3, and CCCTC-binding factor (CTCF) profiles in GM12878. (D) A BRCA1 topologically associated domain (TAD) region (indicated by a thick black bar) was predicted on the basis of the Hi-C data. Normalized Hi-C interacting frequencies were shown as a triangle-like two-dimensional heat map, which was overlaid on ChIP-seq data (C) in GM12878 cells. Red indicates the intensity of the interacting frequencies of the Hi-C data. Chr 17, chromosome 17. (E) 3C-qPCR analysis of long-distance interactions between the BRCA1 promoter and seven enhancer loci [locus 1 to 7 indicated in (A)]. The relative amount of ligation product between the BRCA1 promoter and each of the seven different enhancer loci was plotted. Results from MDA-MB-231, OVCAR10, and VCaP cells treated with DMSO or JQ1 are shown. The data were normalized to a GAPDH loading control. (F) PCR products from the BRCA1 promoter and enhancer locus 2 (E2, top) and from the BRCA1 promoter and enhancer locus 6 (E6, bottom). Ligation sample from bacterial artificial chromosome (BAC) was used as a positive control. No specific PCR product was found in the ligation sample from the BRCA1 promoter and enhancer locus 6, even when the BAC control band was overexposed (shown in red). (G) Quantification of the amount of BRCA1 enhancer locus 2 bound to BRD2/3/4 in MDA-MB-231 cells treated with DMSO or JQ1. (H) Luciferase reporter assay of BRCA1 enhancer activity in MDA-MB-231, OVCAR10, and VCaP cells treated with DMSO, JQ1, olaparib, or JQ1 combined with olaparib. (I) Luciferase reporter assay of BRCA1 enhancer activity in MDA-MB-231, OVCAR10, and VCaP cells treated with BRD2/3/4 siRNA. Lu Yang et al., Sci Transl Med 2017;9:eaal1645 Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works